Nucleai

Nucleai is a company operating at the intersection of artificial intelligence and spatial biology to advance precision medicine. The company was founded in 2017 by Avi Veidman, Eliron Amir, and Lotan Chorev, all veterans of elite Israeli military technology and intelligence units where they specialized in computer vision and AI. The inspiration for the company came from CEO Avi Veidman's personal experience with his father's suspected prostate cancer diagnosis, which involved a lengthy and anxious wait for biopsy results. This experience highlighted the potential to apply the AI and machine learning techniques they had honed for geospatial analysis in the military to the microscopic scale of pathology.

The firm's core offering is the Nucleai ATOM platform, an AI-powered system that analyzes pathology images from biopsies to reveal insights into cancer biology. This platform leverages computer vision and deep learning to analyze complex cellular conversations and spatial relationships within tissue samples. It can process various image types, including H&E, IHC, and multiplex immunofluorescence, to provide a comprehensive view of the tumor microenvironment. The technology extracts patterns and features from these images to help predict patient response to therapies, which is particularly valuable for the development of next-generation treatments like antibody-drug conjugates (ADCs) and immunotherapies. By creating an AI-guided spatial map of a patient's biopsy, the platform assists in identifying novel biomarkers and improving patient stratification for clinical trials.

Nucleai's business model is centered on collaborating with pharmaceutical and biotechnology companies. It licenses its research platform for internal use and engages in joint projects for biomarker discovery. This approach has led to partnerships with a majority of the top 20 biopharma companies, including a notable collaboration with Merck KGaA's venture arm, M Ventures, which also led a significant funding round. The company has steadily grown, securing a total of $60.5 million in funding over four rounds, with the latest being a $14 million investment in April 2024. These funds are aimed at expanding the deployment of its AI technology for patient enrollment in clinical trials, a key step toward integrating predictive diagnostics into standard care.

Keywords: spatial biology, precision medicine, AI pathology, biomarker discovery, cancer diagnostics, immunotherapy, drug development, image analysis, tumor microenvironment, companion diagnostics